[go: up one dir, main page]

CA2288693A1 - Procede d'amelioration de comportements perturbes et de stimulation de l'humeur chez des humains - Google Patents

Procede d'amelioration de comportements perturbes et de stimulation de l'humeur chez des humains Download PDF

Info

Publication number
CA2288693A1
CA2288693A1 CA002288693A CA2288693A CA2288693A1 CA 2288693 A1 CA2288693 A1 CA 2288693A1 CA 002288693 A CA002288693 A CA 002288693A CA 2288693 A CA2288693 A CA 2288693A CA 2288693 A1 CA2288693 A1 CA 2288693A1
Authority
CA
Canada
Prior art keywords
dronabinol
patients
dementia
administered
humans
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002288693A
Other languages
English (en)
Inventor
Ladislav Volicer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unimed Pharmaceuticals LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/866,511 external-priority patent/US5804592A/en
Application filed by Individual filed Critical Individual
Publication of CA2288693A1 publication Critical patent/CA2288693A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention se rapporte à un procédé d'amélioration des comportements perturbés et de stimulation de la bonne humeur chez des sujets atteints de démence, notamment chez des humains atteints de démence telle que celle liée à la maladie d'Alzheimer, ledit procédé consistant en l'administration de dronabinol.
CA002288693A 1997-05-07 1998-05-06 Procede d'amelioration de comportements perturbes et de stimulation de l'humeur chez des humains Abandoned CA2288693A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4581397P 1997-05-07 1997-05-07
US60/045,813 1997-05-07
US08/866,511 1997-05-30
US08/866,511 US5804592A (en) 1997-05-30 1997-05-30 Method for improving disturbed behavior and elevating mood in humans
PCT/US1998/009269 WO1998050027A1 (fr) 1997-05-07 1998-05-06 Procede d'amelioration de comportements perturbes et de stimulation de l'humeur chez des humains

Publications (1)

Publication Number Publication Date
CA2288693A1 true CA2288693A1 (fr) 1998-11-12

Family

ID=26723227

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002288693A Abandoned CA2288693A1 (fr) 1997-05-07 1998-05-06 Procede d'amelioration de comportements perturbes et de stimulation de l'humeur chez des humains

Country Status (6)

Country Link
EP (1) EP1019041A4 (fr)
JP (1) JP2002501510A (fr)
AU (1) AU743788B2 (fr)
CA (1) CA2288693A1 (fr)
IL (1) IL132784A (fr)
WO (1) WO1998050027A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US20210023053A1 (en) 2018-03-30 2021-01-28 India Globalization Capital, Inc. Method and composition for treating cns disorders
CN113993523A (zh) 2019-04-17 2022-01-28 指南针探路者有限公司 用赛洛西宾治疗抑郁症和其他各种病症

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92238A (en) * 1989-11-07 1995-07-31 Yissum Res Dev Co ADMN blocking product containing tetrahydrocannabinol history, several new tetrahydrocannabinol histories and process for their preparation
US5521215A (en) * 1989-11-07 1996-05-28 Ramot University Authority For Applied Research And Industrial Development Ltd. NMDA-blocking pharmaceuticals
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists

Also Published As

Publication number Publication date
IL132784A0 (en) 2001-03-19
EP1019041A4 (fr) 2002-04-17
AU7291698A (en) 1998-11-27
JP2002501510A (ja) 2002-01-15
EP1019041A1 (fr) 2000-07-19
IL132784A (en) 2004-07-25
WO1998050027A1 (fr) 1998-11-12
AU743788B2 (en) 2002-02-07

Similar Documents

Publication Publication Date Title
US5804592A (en) Method for improving disturbed behavior and elevating mood in humans
Robinson et al. Sodium oxybate: a review of its use in the management of narcolepsy
Campbell et al. Naltrexone in autistic children: behavioral symptoms and attentional learning
Lockman et al. Relief of pain of Fabry's disease by diphenylhydantoin
RU2281771C2 (ru) Использование декстрометорфана и ингибитора оксидазы для отучения пациентов от наркотиков и антидепрессантов
Holbrook et al. Diagnosis and management of acute alcohol withdrawal
US20060252761A1 (en) Augmentation of extinction via administration of sub-antimicrobial doses of D-cycloserine
EP2214683B1 (fr) Dosage unitaire pour la sante cerebrale
TW201900158A (zh) 使用氟苯丙胺治療杜希氏徵候群之方法
US20100178362A1 (en) Chromium complexes for improvement of memory and cognitive function
CN104582793A (zh) 用拉喹莫德和氨吡啶的组合治疗多发性硬化症
KR100530879B1 (ko) 알카노일 카르니틴 유도체를 함유한 주의력-결핍 및 과잉행동 장애 치료용 약제조성물
Adler et al. Reversal of diminished inhibitory sensory gating in cocaine addicts by a nicotinic cholinergic mechanism
AU743788B2 (en) Method of improving disturbed behavior and elevating mood in humans
George et al. Cannabis toxicity in children and adolescents
EP2163244B1 (fr) Utilisation de polyprénols pour la préparation d'une composition pharmaceutique pour le traitement de la dépendance à l'alcool éthylique et/ou aux drogues
MX2007008321A (es) Composicion farmaceutica que comprende la combinacion de una triazolobenzodiazepina y un agente inhibidor selectivo de la recaptura de serotonina.
MXPA99010187A (en) Method of improving disturbed behavior and elevating mood in humans
US5863925A (en) Use of sulbutiamine in the treatment of Parkinson's disease, schizophrenia, alcoholism, and dysthymia
Lask Treatment of Vomiting of Pregnancy with Antihistamines
AU749169B2 (en) A method for preventing the onset of asthma
WO2012057635A1 (fr) Agent d'atténuation de lésions cérébrales traumatiques
Adams The Gordon Wilson Lecture. Nutritional Diseases of the Nervous System in the Alcoholic Patient
Shua-Haim et al. Donepezil (AriceptTM): The caregivers voice and clinical impression
Safer Drug treatment in child psychiatry

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20150506